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STRATEGIES	TO	CONTINUE	STATIN	USE		 	 3		 Abstract	Nothing	has	proven	to	be	as	effective	in	the	treatment	of	coronary	heart	disease	as	hydroxymethylglutaryl	coenzyme	A	(HMG-CoA)	reductase	inhibitors,	or	statins,	and	since	heart	disease	continues	to	be	the	leading	cause	of	death	in	the	United	States,	it	is	imperative	for	patients	to	be	able	to	tolerate	and	maintain	statin	therapy.		Even	though	statins	are	known	to	have	an	impressive	safety	profile	and	are	generally	well	tolerated,	discontinuation	of	therapy	does	occur,	and	is	most	often	due	to	myalgia	symptoms.		The	patient	presented	in	the	case	report	was	diagnosed	with	familial	hypercholesterolemia,	and	statin	therapy	is	a	vital	piece	of	the	treatment	plan.		The	goal	of	this	literature	review	is	to	evaluate	both	alternative	statin	dosing	and	vitamin	D	supplementation	to	determine	if	using	either	of	these	strategies	allows	patients	to	continue	statin	therapy,	thus	reducing	both	morbidity	and	mortality	by	decreasing	the	risk	of	future	cardiovascular	events.					
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Background	and	Rationale		 Heart	disease,	accounting	for	600,000	deaths	annually,	continues	to	be	the	leading	cause	of	death	in	the	United	States.		Hypercholesterolemia	is	one	of	the	major	risk	factors	for	developing	heart	disease	(Centers	for	Disease	Control	and	Prevention,	[CDC],	2014).		Additionally,	according	to	the	CDC	(2014),	“Several	genetic	disorders	are	associated	with	increased	risk	of	premature	heart	attacks.		A	relatively	common	disorder	is	familial	hypercholesterolemia,	which	causes	high	levels	of	‘bad’	cholesterol	(low	density	lipoprotein,	or	LDL	cholesterol)	beginning	at	birth”	(para.	2).		Cholesterol,	a	fat-like,	waxy	substance,	is	a	component	of	all	body	cells.		It	plays	a	necessary	role	in	the	production	of	hormones	and	vitamin	D,	as	well	as	aiding	in	food	digestion.		Our	bodies	are	capable	of	making	all	the	cholesterol	it	needs	to	carry	out	these	functions.		Therefore,	the	additional	cholesterol	found	in	dietary	sources	needs	to	be	removed	via	high-density	lipoproteins,	or	HDL,	which	is	often	referred	to	as	the	“good”	cholesterol.		The	“bad”	cholesterol,	or	LDL	as	mentioned	previously,	causes	buildup	of	plaque	leading	to	atherosclerosis,	which	results	in	a	decrease	of	oxygen-rich	blood	flow	through	the	arteries	supplying	the	heart	and	thus	the	rest	of	the	body	(National	Heart,	Lung,	and	Blood	Institute,	[NHLBI],	2014).		This	process	leads	to	coronary	artery	disease	(CAD)	also	called	coronary	heart	disease	(CHD),	the	most	common	form	of	heart	disease	(CDC,	2015;	NHLBI,	2014).		Coronary	heart	disease	can	lead	to	heart	failure,	arrhythmias,	heart	attack,	and	stroke	(NHLBI,	2015).		 Sully,	a	24-year-old	male	and	the	patient	presented	in	this	case	report,	was	diagnosed	with	familial	hypercholesterolemia.		This	inherited	condition	of	elevated	
STRATEGIES	TO	CONTINUE	STATIN	USE		 	 5		cholesterol	can	cause	CAD	leading	to	heart	attacks	at	an	early	age	(National	Human	Genome	Research	Institute,	[NHGRI],	2013).		According	to	the	NHGRI	(2013),	“Men	who	have	familial	hypercholesterolemia	have	heart	attacks	in	their	40’s	to	50’s,	and	85	percent	of	men	with	the	disorder	have	a	heart	attack	by	age	60,”	(What	is	familial	hypercholesterolemia,	para.	5).		The	inherited	condition	is	a	result	of	a	gene	mutation	on	chromosome	number	19,	which	is	responsible	for	removing	LDL	from	the	bloodstream.		This	alteration	results	in	high	levels	of	LDL	beginning	at	birth	(NHGRI,	2013).		The	fasting	lipid	panel	drawn	on	the	patient	in	this	case	report	revealed	elevated	cholesterol	and	LDL;	additionally,	his	father	also	had	hypercholesterolemia	and	died	of	a	heart	attack	at	the	age	of	55.		These	factors	led	to	the	familial	hypercholesterolemia	diagnosis.		 The	treatment	of	familial	hypercholesterolemia	has	several	aspects	including	diet,	exercise,	weight	management,	and	medication	(NHLBI,	2005).		Statins	are	generally	the	medication	of	choice	in	hypercholesterolemia	treatment	(Reinhart	&	Woods,	2012).		Statins	inhibit	cholesterol	formation	in	the	liver	along	with	increasing	liver	cell	receptors	that	are	responsible	for	removing	LDL	from	the	bloodstream	(Gotto,	2002).		Studies	have	shown	statins	to	decrease	LDL	by	20	to	40%,	and	in	some	cases	by	even	greater	than	40%	depending	on	the	drug	and	dosage	(Weng,	Kao	Yang,	Lin,	&	Tai,	2009).		Even	though	statins	are	generally	well	tolerated,	studies	have	revealed	that	as	many	as	20%	of	patients	discontinue	use	due	to	reported	myalgias.		This	adverse	side	effect	of	statin	therapy	is	not	well	understood,	and	it	can	be	challenging	to	differentiate	it	from	other	possible	causes.		Clinically,	myalgias	are	of	concern	due	to	the	risk	of	rhabdomyolysis,	which	is	severe	
STRATEGIES	TO	CONTINUE	STATIN	USE		 	 6		muscle	damage	that	can	lead	to	kidney	damage	and	even	death	(Reinhart	&	Woods,	2012;	Thompson,	Clarkson,	&	Rosenson,	2006).		The	efficacy	of	alternative	therapies	has	not	proven	to	equal	that	of	statins,	specifically	when	speaking	“in	terms	of	mortality	risk	reduction”	(Reinhart	&	Woods,	2012,	p.	292).		As	stated	by	Reinhart	and	Woods	(2012),	“any	strategy	capable	of	preventing	repeat	myalgia	in	these	patients	will	help	enable	their	continued	use	of	statin	medication	and	help	lower	the	morbidity	and	mortality	associated	with	CHD”	(p.	292).		Alternative	dosing	and	adding	vitamin	D	supplementation	to	reduce	myalgia	symptoms	and	maintain	statin	therapy	are	two	strategies	that	have	been	studied.		Therefore,	the	purpose	of	this	literature	review	is	to	determine	if	either	strategy	will	effectively	assist	in	the	goal	of	continuing	statin	therapy	in	patients	with	reported	myalgia.	
Case	Report	
Chief	Complaint:	requesting	cholesterol	check	r/t	family	history		
HPI:		This	24-year-old	male	presents	today	requesting	to	have	his	cholesterol	checked.		Patient	states	his	mother	encouraged	him	to	come	in	because	his	father,	who	had	elevated	cholesterol,	recently	died	of	a	heart	attack.		Patient	denies	chest	pain,	palpitations,	hypertension,	or	shortness	of	breath.		
Past	Medical	History:	allergic	rhinitis		
Past	Surgical	History:	tonsillectomy	and	adenoidectomy	at	age	4		
Family	History:	Father	–	died	at	age	55	from	a	heart	attack,	Mother	–	alive	and	well,	Brother	–	hypercholesterolemia,	age	27	
	
Social	History:	Patient	is	an	EMT	and	does	shift	work.		Reports	exercising	for	30	minutes	4-5	days	per	week.			Patient	denies	caffeine	intake,	smoking,	and	recreational	drug	use.		Reports	frequent	fast	food	intake	and	drinks	2	beers	each	evening	along	with	social	drinking	1-2	weekends	per	month	where	he	consumes	5-6	drinks	on	those	occasions.				
Medications:	Zyrtec	prn		
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Allergies:	NKA		
ROS:	
Constitutional:	denies	fatigue,	recent	weight	change,	fever,	trouble	sleeping	
Cardiovascular:	denies	chest	pain,	palpitations,	hypertension,	edema	
Respiratory:	denies	shortness	of	breath	
Psychological:	denies	anxiety,	depression,	mood	changes		
Physical	Exam:	
Vitals:	BP	110/54,	HR	62,	Temp	37.1	c,	Ht	6’1”,	Wt	200	lbs.,	BMI	26.4	
General:	alert,	well	developed,	no	acute	distress	
Skin:	color	normal	
Cardiovascular:	S1	and	S2,	no	murmurs,	regular	rate,	no	JVD	or	edema	noted	
Respiratory:	respiration	rhythm	and	depth	normal,	clear	to	auscultation	
Psychiatric:	normal	affect,	normal	mood		
Labs:	Lipid	panel:	 	 	 	 BMP:	 	 	 	 				LFT:	Cholesterol	–	310	 	 	 BUN	–	18	 	 	 				Albumin	–	4.0	 	Triglycerides	–	140	 	 	 Sodium	–	139		 	 				Alk	Phos	-	88	HDL	–	60	 	 	 	 Potassium	–	3.9	 	 				Total	bili	–	0.4	LDL	–	209	 	 	 	 Chloride	–	102	 	 				AST	-	20		 	 	 	 	 CO2	–	27.3	 	 	 				ALT	-	22	Glucose	–	86	 	 	 				Total	protein	–	7.4	Creatinine	–	1.1	Calcium	–	9.8	Anion	gap	–	9.7	GFR	-	>60	Albumin	–	4.00	Alk	Phos	–	88	Total	Protein	–	7.4	
	
Impression/Plan:	1.		Familial	Hypercholesterolemia	–	start	Lipitor	20mg	daily,	discussed	importance	of	compliance	and	medication	side	effects,	follow	a	low	cholesterol	diet	and	reduce	saturated	fat	intake,	continue	exercise	regimen,	maintain	weight.			Patient	verbalized	understanding	of	above	plan	and	is	agreeable.		Patient	encouraged	to	call	with	any	questions	or	concerns.			Follow-up	in	3	months	with	fasting	labs.		Will	recheck	lipid	panel.		Will	consider	dietary	consult	at	this	time.	
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Literature	Search	Strategy		 A	literature	search	was	conducted	utilizing	both	CINAHL	and	PubMed	databases	via	the	University	of	North	Dakota	Harley	E.	French	Library	of	the	Health	Sciences	website.		An	advanced	search	in	PubMed	was	completed	using	the	medical	subject	heading	(MeSH)	terms	of	“statins”	AND	“alternate	dosing.”		The	search	generated	22	articles.		The	“English	language”	and	“published	within	the	last	10	years”	filters	were	added,	reducing	the	articles	to	17.		After	reviewing	all	17	articles,	one	appeared	to	be	most	related	to	the	clinical	question	but	was	not	included	in	this	review;	however,	the	“similar	articles”	feature	attached	to	this	particular	article	was	utilized	and	an	additional	136	articles	were	generated.		After	reviewing	the	articles,	three	were	determined	to	be	relevant.		Review	of	the	reference	sections	of	the	three	articles	resulted	in	two	additional	articles,	which	were	retrieved	using	PubMed.		An	additional	search	in	PubMed	using	the	MeSH	terms	of	“statin	intolerance”	AND	“vitamin	D	supplementation”	and	again	including	the	“English	language”	and	“published	within	the	last	10	years”	filters,	generated	eight	articles	for	review.		Two	of	these	articles	were	determined	to	be	pertinent	to	the	research	question.		An	additional	article	was	found	and	retrieved	via	PubMed	after	review	of	the	reference	sections.		The	CINAHL	search	was	conducted	using	the	search	terms	“statin”	AND	“myalgia.”		This	search	resulted	in	67	articles.		The	“English	language”	and	“published	within	the	last	10	years”	filters	were	added	reducing	the	articles	to	57.		After	review,	one	was	found	to	be	pertinent	to	the	research	question,	and	one	additional	article	was	obtained	via	PubMed	after	review	of	the	reference	section.		Thus,	the	literature	search	produced	a	total	of	10	articles.	
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Literature	Review		Alternative	Dosing	
	 Patient	benefit	from	statin	therapy	is	well	documented,	and	research	has	proven	that	it	is	essential	in	the	treatment	of	CHD	especially	in	reducing	morbidity	and	mortality.		Statin	intolerance	due	to	myalgia	often	leads	to	discontinuation	of	this	life-saving	medication.		Alternative	statin	dosing	is	one	strategy	that	has	been	studied	to	determine	if	it	leads	to	decreased	intolerance,	thus	allowing	patients	to	continue	on	therapy	(Reinhart	&	Woods,	2012).		Rosuvastatin	and	atorvastatin	are	the	two	medications	most	often	studied	as	their	long	half-life	provides	the	greatest	chance	to	achieve	therapeutic	levels	with	less	frequent	dosing	(Gadarla,	Kearns,	&	Thompson,	2008;	Kennedy,	Barnas,	Schmidt,	Glisczinski,	&	Paniagua,	2011).		In	the	randomized	controlled	trial	(RCT)	presented	by	Kennedy	et	al.	(2011),	17	patients	were	evaluated.		The	patients	all	had	a	diagnosis	of	hypercholesterolemia	and	were	deemed	statin	intolerant	due	to	myalgia.		The	patients	were	not	currently	on	statin	therapy	and	were	not	meeting	LDL	goals	according	to	the	Adult	Treatment	Panel	III	(ATP	III)	National	Cholesterol	Education	Panel	(NCEP)	Guidelines.		The	study	had	two	eight-week	phases	and	the	participants	switched	treatment	arms	after	the	first	phase.		Patients	were	given	once-weekly	rosuvastatin	5	mg	or	a	placebo	for	four	weeks,	and	if	they	were	not	at	LDL	goal	after	the	first	four	weeks,	the	dose	was	increased	to	10	mg.		Patients	were	required	to	remain	consistent	with	their	lifestyle	habits	throughout	the	study.		A	12.2%	reduction	in	LDL	was	noted	in	the	patients	who	were	given	once-weekly	rosuvastatin	versus	0.4%	reduction	in	the	placebo	group,	and	20%	attained	LDL	goal	while	zero	patients	met	goal	on	placebo.		
STRATEGIES	TO	CONTINUE	STATIN	USE		 	 10		Furthermore,	11.8%	of	patients	reported	myalgia	while	on	the	placebo	treatment,	and	20%	reported	myalgia	while	on	rosuvastatin	leading	to	therapy	cessation	(Kennedy	et	al.,	2011).		The	authors	concluded,	“Once-weekly	low-dose	rosuvastatin	is	an	effective	and	well-tolerated	lipid-lowering	therapy	option	for	patients	not	at	LDL	goal	and	previously	unable	to	tolerate	statins	because	of	a	history	of	myalgias”	(Kennedy	et	al.,	2011,	p.	308).		In	an	RCT	conducted	by	Jafari,	Ebrahimi,	Ahmadi-Kashani,	Balian,	and	Bashir	(2003),	54	patients	were	included	in	the	study	after	meeting	the	criteria	of	an	LDL	ranging	from	100	to	200	mg/dL	as	well	as	meeting	the	parameters	considered	appropriate	for	treatment	per	the	NCEP	guidelines.		Therefore,	patients	with	abnormal	liver	enzymes	or	creatine	kinase	(CK),	patients	currently	taking	another	cholesterol-reducing	medication,	those	pregnant	or	breastfeeding,	or	those	who	experienced	previous	intolerance	to	statin	therapy	were	excluded.		The	six-week	trial	included	three	randomized	groups	who	received	either	atorvastatin	10	mg	every	day,	10	mg	every	other	day,	or	20	mg	every	other	day.		The	groups	were	relatively	similar	when	considering	age,	gender,	and	weight.		Out	of	54	patients,	46	finished	the	study.		Those	who	did	not	complete	the	study	did	not	come	to	their	six-week	follow-up	and	were	thus	labeled	as	dropouts.		Patients	were	evaluated	with	fasting	lipids,	liver	function,	and	CK	tests.		All	three	groups	saw	a	significant	reduction	in	LDL	and	total	cholesterol,	and	those	who	took	atorvastatin	20	mg	every	other	day	also	experienced	a	significant	increase	in	HDL.		All	regimens	evaluated	were	deemed	well	tolerated	as	no	myalgia	was	reported,	no	significant	increase	in	liver	enzymes	or	CK	was	noted,	and	therapy	compliance	was	achieved.		These	study	
STRATEGIES	TO	CONTINUE	STATIN	USE		 	 11		results	indicate	that	alternate	atorvastatin	dosing	is	effective	and	safe	(Jafari	et	al.,	2003).	A	RCT	evaluating	35	patients	was	conducted	by	Matalka,	Ravnan,	and	Deedwania	(2002).		The	study	required	diagnosed	hypercholesterolemia	participants	to	be	at	least	18	years	of	age	and	to	meet	NCEP	ATP	II	treatment	guidelines.		If	patients	were	currently	taking	a	cholesterol-lowering	medication,	the	medication	was	discontinued	and	the	study	was	started	six	weeks	later.		Patients	were	excluded	with	triglycerides	over	400	mg/dL,	uncontrolled	diabetes	with	blood	glucose	greater	than	200	mg/dL,	or	three-month	history	of	either	myocardial	infarction,	percutaneous	transluminal	coronary	angioplasty,	or	coronary	artery	bypass	graft.		The	study	also	excluded	patients	with	liver	enzymes	greater	than	three	times	the	upper	limit	of	normal,	those	who	consume	more	than	10	alcoholic	beverages	per	week,	along	with	those	taking	azole	antifungal	medications,	warfarin,	or	any	immunosuppressants.		The	patients	were	assigned	randomly	to	receive	either	atorvastatin	10	mg	every	day	or	every	other	day	for	a	period	of	12	weeks.		The	dose	was	doubled	at	the	six-week	interval	if	the	patient	was	not	meeting	LDL	goal.		Lipid	levels	were	assessed	at	baseline,	six	weeks,	and	again	at	12	weeks.		Additional	labs	were	drawn	in	order	to	evaluate	safety,	which	included	a	complete	blood	count,	chemistry	panel,	CK,	and	liver	function	tests.		At	the	six-week	point,	patients	showed	an	LDL	reduction	of	27%	in	the	alternate-day	group	and	38%	in	the	every-day	group.		Results	at	the	12-week	interval	included	a	35%	LDL	reduction	in	the	alternate-day	group	and	a	38%	reduction	in	the	every-day	group.		Unfortunately,	there	was	also	a	decrease	in	HDL	at	12	weeks	in	both	groups.		The	dose	was	doubled	
STRATEGIES	TO	CONTINUE	STATIN	USE		 	 12		in	79%	of	those	taking	atorvastatin	every	other	day	compared	to	17%	of	the	patients	taking	the	medication	daily.		Goal	in	LDL	levels	was	achieved	by	43%	of	those	in	the	alternate-day	group	versus	75%	of	patients	in	the	every-day	group.		Only	one	patient	had	to	be	withdrawn	from	the	study	due	to	muscle	weakness	(Matalka,	Ravnan,	&	Deedwania,	2002).		As	stated	by	Matalka,	Ravnan,	and	Deedwania	(2002),	“The	study	showed	that	the	efficacy	of	alternate-day	administration	of	atorvastatin	is	comparable	to	that	of	daily	administration	in	reducing	LDL-C	in	patients	with	hypercholesterolemia”	(p.	676).		A	retrospective	chart	review	of	40	patients	who	were	considered	statin	intolerant	due	to	myalgia	were	given	rosuvastatin	twice	weekly	for	at	least	three	weeks.		Thirty	patients	were	given	5	mg	while	10	were	given	10	mg	each	week	on	Mondays	and	Thursdays.		Twenty-four	of	the	patients	were	also	taking	ezetimibe,	fibrates,	resins,	and	Chinese	red	rice,	either	alone	or	in	combination.		However,	the	twice-weekly	rosuvastatin	dosing	schedule	decreased	total	cholesterol	by	19%	and	reduced	LDL	by	26%,	as	well	as	resulting	in	a	14%	reduction	in	triglycerides.		No	significant	change	was	noted	in	HDL	levels.		Eight	patients	were	forced	to	discontinue	therapy	due	to	muscle	aches,	which	means	80%	of	the	patients	studied	were	able	to	tolerate	the	therapy.		The	authors	concluded	that	dose	reduction	contributes	to	decreased	statin	intolerance	possibly	by	allowing	muscle	recovery	with	intermittent	dosing	(Gadarla	et	al.,	2008).				 Another	retrospective	chart	review	conducted	by	Backes	et	al.	(2008)	included	51	patients	who	received	rosuvastatin	on	an	alternate	dosing	schedule	of	every	other	day	for	at	least	one	month.		All	of	the	patients	had	documented	statin	
STRATEGIES	TO	CONTINUE	STATIN	USE		 	 13		intolerance	and	lipid	levels	drawn	prior	to	and	after	treatment.		The	results	of	the	study	revealed	significant	reductions	(p	<	0.001)	in	triglycerides,	LDL,	and	total	cholesterol	without	significant	changes	in	HDL.		Furthermore,	64.9%	of	the	patients	met	the	NCEP	ATP	III	LDL-C	goal.		Of	the	51	patients,	37	were	able	to	tolerate	the	alternate	dosing,	whereas	14	had	return	of	myalgia	symptoms	and	were	forced	to	discontinue	therapy.		The	authors	theorized	that	alternate	dosing	of	rosuvastatin,	specifically	every	other	day,	can	still	result	in	adequate	LDL	reduction	while	avoiding	therapy	ending	adverse	effects	such	as	myalgia.		Thus,	patients	are	better	treated	with	alternate	dosing	than	not	being	treated	at	all	(Backes	et	al.,	2008).		Also,	as	stated	by	Backes	et	al.	(2008),	“Rosuvastatin	appears	to	be	a	rational	choice	for	markedly	improving	lipoprotein	levels	in	statin-intolerant	patients	because	of	its	high	potency,	long	half-life,	and	lack	of	CYP3A4	metabolism”	(p.	342).		However,	the	authors	did	recognize	some	study	limitations	including	the	study’s	retrospective	design,	small	sample	size,	and	the	fact	that	changes	made	in	lifestyle	modifications	by	individual	patients	were	not	evaluated	and	were	not	discouraged	(Backes	et	al.,	2008).	
Vitamin	D	Supplementation	
	 A	deficiency	in	vitamin	D	can	lead	to	myalgia,	which	is	often	the	first	manifestation	identified	(Sikka	et	al.,	2011).		Since	statin	intolerance	is	most	commonly	caused	by	myalgia,	there	is	consideration	that	investigating	vitamin	D	levels	and	thus	correcting	any	deficiency	can	help	continue	statin	use	by	resolving	myalgia	symptoms	(Khayznikov	et	al.,	2015).		In	the	prospective	cohort	study	presented	by	Khayznikov	et	al.	(2015),	146	patients	were	assessed.		Patients	
STRATEGIES	TO	CONTINUE	STATIN	USE		 	 14		included	were	considered	statin	intolerant	by	failing	therapy	of	two	or	more	agents	along	with	low	serum	vitamin	D	levels	less	than	32	ng/mL.		Patients	with	previously	reported	rhabdomyolysis,	those	taking	corticosteroids,	or	those	with	any	comorbidity	that	could	lead	to	muscle	or	bone	pain	were	excluded.		The	patients	were	given	either	50,000	or	100,000	units	per	week	of	vitamin	D2	to	correct	the	deficiency.		Vitamin	D	doses	were	adjusted	to	maintain	a	normal	range	of	50	to	80	ng/mL.		Patients	were	then	given	rosuvastatin	10	to	20	mg	daily	three	weeks	after	the	vitamin	D	initiation.		Statin	dosing	was	also	adjusted	in	an	attempt	to	reduce	LDL	to	meet	ATP	III	goals.		Patients	completed	follow-up	at	six	months,	12	months,	and	24	months	(Khayznikov	et	al.,	2015).		Of	the	146	patients,	88	to	95%	were	able	to	tolerate	statin	therapy	without	recurrent	“myalgia,	myositis,	myopathy,	and/or	myonecrosis”	with	median	vitamin	D	supplementation	of	50,000	units	per	week	(Khayznikov	et	al.,	2015,	p.	90).		The	authors	concluded	that	statin	intolerance	due	to	adverse	muscular	effects	is	associated	with	vitamin	D	deficiency	and	can	be	resolved	by	supplementation.		Additionally,	vitamin	D	has	proven	to	be	well	tolerated	and	its	safety	is	not	a	concern	(Khayznikov	et	al.,	2015).		 In	another	prospective	cohort	designed	study,	the	goal	of	the	authors	was	to	determine	if	low	serum	vitamin	D	levels	correlate	to	myalgia	in	patients	on	statin	therapy,	and	if	the	symptoms	can	be	reversed	by	adding	supplementation.		Of	the	621	patients	who	had	vitamin	D	levels	drawn,	128	complained	of	myalgia.		The	vitamin	D	levels	were	low	in	64%,	or	82,	of	the	patients	with	myalgia	symptoms	compared	to	43%	of	the	patients	without	symptoms.		Of	the	82	patients	with	myalgia,	38	had	vitamin	D	levels	below	32	ng/mL	and	were	instructed	to	take	
STRATEGIES	TO	CONTINUE	STATIN	USE		 	 15		50,000	units	per	week	of	vitamin	D	for	12	weeks.		They	were	allowed	to	continue	their	current	statin	medication,	which	included	rosuvastatin,	atorvastatin,	or	pravastatin	(Ahmed	et	al.,	2009).		At	the	end	of	the	study	period,	Ahmed	et	al.	(2009)	determined,	“vitamin	D	supplementation	that	normalized	serum	vitamin	D	levels	was	concurrently	associated	with	resolution	of	myalgias	in	35	of	38	(92%)	statin-treated	patients	with	myalgia	and	low	pretreatment	serum	vitamin	D	levels”	(p.	15).		The	authors	did	recognize	some	study	limitations,	which	included	subjective	reporting	of	myalgia	symptoms	by	patients,	lack	of	blinding,	and	not	having	a	control	group	(Ahmed	et	al.,	2009).		 Glueck,	Abuchaibe,	and	Wang	(2011)	also	presented	a	prospective	study	where	68	patients	diagnosed	with	hypercholesterolemia,	unable	to	tolerate	at	least	one	statin	due	to	myositis/myalgia,	and	with	low	serum	25	(OH)	vitamin	D	levels	less	than	32	ng/mL	were	evaluated	to	identify	if	vitamin	D	deficiency	correction	would	result	in	tolerance	of	statin	therapy.		Patients	were	given	50,000	units	of	vitamin	D2	twice	weekly	for	three	weeks	and	then	they	continued	once	weekly	dosing.		Statin	therapy	was	restarted	after	the	initial	three	weeks	of	vitamin	D	supplementation.		Patients	were	assessed	at	three	months,	and	91%	of	the	patients	were	able	to	tolerate	statin	therapy	with	vitamin	D	supplementation	(Glueck,	Abuchaibe,	&	Wang,	2011).		 A	retrospective	chart	review	of	450	patients	taking	simvastatin	80	mg	was	conducted	and	found	that	11.1%	of	patients	reported	myalgia	along	with	one	patient,	or	0.22%,	who	developed	rhabdomyolysis.		The	study	aimed	to	determine	whether	or	not	low	vitamin	D	levels	contribute	to	the	risk	of	developing	myalgia	
STRATEGIES	TO	CONTINUE	STATIN	USE		 	 16		while	on	statin	therapy.		Many	variables	were	considered	in	this	analysis	including	baseline	laboratory	values,	comorbidities,	medications,	and	demographics.		The	results	of	the	study	revealed	a	vitamin	D	level	less	than	25	ng/mL	correlates	to	a	25%	incidence	in	myalgia	compared	to	7.89%	in	those	with	levels	greater	than	25	ng/mL.		The	authors	suggest	that	this	association	indicates	the	need	for	serum	vitamin	D	monitoring	and	deficiency	correction	in	order	to	decrease	myalgia	in	patients	on	statin	therapy,	specifically	high-dose	simvastatin	(Mergenhagen	et	al.,	2014).					 	Another	retrospective	study	assessed	272	patients	aged	33	to	89	years	of	age	and	aimed	to	evaluate	the	possibility	of	a	relationship	between	vitamin	D	levels	and	adverse	muscle	effects	in	patients	on	statin	therapy	(Eisen	et	al.,	2014).		Exclusion	criteria	included	“conditions	known	to	predispose	to	myalgia,	CK	elevation,	or	vitamin	D	insufficiency	such	as	hypothyroidism,	renal	failure	(creatinine	>	1.2	mg/dl),	active	participation	in	competitive	sports,	known	myopathy,	vitamin	D	supplementation,	acute	coronary	syndrome,	and	elevated	baseline	plasma	CK	level”	(Eisen	et	al.,	2014,	p.	42-43).			The	analysis	compared	vitamin	D	levels	and	the	incidence	of	low	vitamin	D	levels	to	myalgia,	CK	elevation,	or	any	reported	muscular	adverse	effect.		Variables	considered	included	age,	gender,	hypertension,	diabetes,	smoking,	CAD,	and	family	history	of	premature	CAD.		The	study	did	not	find	a	statistically	significant	relationship	between	vitamin	D	levels	and	reports	of	myalgia,	CK	elevation,	or	any	muscular	adverse	effect.		Therefore,	the	authors	concluded	that	there	is	no	correlation	between	vitamin	D	levels	and	adverse	muscular	effects	in	patients	on	statin	therapy.		However,	the	authors	did	
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Summary		 In	the	alternative	statin	dosing	studies	included	in	this	literature	review,	recurrent	myalgia	symptoms	were	reported	in	0	to	27%	of	the	patients.		Atorvastatin	faired	just	slightly	better	than	rosuvastatin	when	considering	recurrent	myalgia	rates.		Alternative	dosing	appeared	to	be	effective	and	led	to	significant	LDL	reduction.		Some	studies	demonstrated	a	significant	reduction	in	total	cholesterol	and	triglycerides	as	well.		However,	the	studies	reviewed	suggested	that	statin	therapy	given	in	lower	doses	does	not	have	an	effect	on	HDL.		Regardless,	alternative	dosing	appeared	to	be	an	acceptable	strategy	to	continue	statin	use	in	patients	with	myalgia.		Additionally,	the	importance	of	statin	therapy	in	preventing	life-threatening	cardiovascular	events	leads	to	the	suggestion	that	patients	are	better	treated	at	lower	doses	or	more	infrequent	doses	than	to	not	be	treated	at	all.			Vitamin	D	supplementation	appeared	to	be	a	bit	more	controversial.		However,	most	studies	reviewed	did	find	a	relationship	between	low	vitamin	D	levels	and	statin-induced	myalgia	with	one	study	reporting	the	correlation	at	25%.		Three	of	the	studies	reported	that	vitamin	D	supplementation	prevented	recurrent	myalgia	symptoms	at	rates	of	91,	92,	and	95%.		The	results	in	the	studies	reviewed	at	least	warrant	vitamin	D	level	monitoring	and	correction	of	deficiency	in	an	attempt	to	continue	statin	therapy	in	patients	with	myalgia.			The	research	suggested	that	alternative	statin	dosing	and	vitamin	D	supplementation	have	potential	to	allow	continuation	of	therapy	in	patients	with	
STRATEGIES	TO	CONTINUE	STATIN	USE		 	 18		myalgia.		However,	further	investigation	is	needed	to	verify	these	results	as	only	three	of	the	studies	reviewed	were	RCTs,	and	most	of	the	studies	had	fairly	small	sample	sizes.		Furthermore,	guideline	development	will	need	to	be	completed	in	order	for	practitioners	to	most	effectively	treat	patients	experiencing	myalgia	on	statin	therapy.		
Learning	Points	
§ Statin	therapy	is	the	most	effective	treatment	for	CAD	proven	by	reduction	in	morbidity	and	mortality.	
§ Discontinuation	of	therapy	is	most	commonly	a	result	of	myalgia	symptoms.	
§ Alternative	statin	dosing,	(specifically	when	using	atorvastatin	and	rosuvastatin	due	to	their	longer	half-life),	at	lower	doses	and/or	decreased	frequency	has	the	potential	to	allow	patients	who	experience	therapy	limiting	myalgias	on	standard	dosing	to	continue	therapy.	
§ Vitamin	D	levels	should	be	monitored,	supplementation	should	be	initiated	to	correct	deficiency,	and	statin	therapy	should	be	rechallenged	when	levels	normalize.	
§ Strategies	to	continue	statin	use	in	patients	with	myalgia	should	be	explored	by	practitioners	and	attempts	should	be	made	to	continue	their	use.						
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